Compound Detail
CHEMBL4795082
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
CCc1c2c(nc3ccc(OCC(=O)N4CCCCC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)[C@]3(O)CC
Basic Information
| ChEMBL ID | CHEMBL4795082 |
| Phase | Preclinical |
| Structure Type | MOL |
| InChI Key | QCYRDOFAEZEQFE-LJAQVGFWSA-N |
7
Targets
7
Activities
1
Assay Types
13
PK Parameters
10
Publications
0
Known Names
Molecular Properties
517.6
MW (Da)
3.03
ALogP
8
HBA
1
HBD
111.0
PSA (Ų)
0.41
QED
1
Ro5 Violations
5
Rot. Bonds
Drug Information
| Molecule Type | Unknown |
| Availability | Unknown |
| Chirality | Unknown |
Activity Summary
IC50 7 meas. best 8.7
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Raji CHEMBL614628 | IC50 | 8.7 | 8.7 | 2.0 | 1 |
| HCT-116 CHEMBL394 | IC50 | 8.52 | 8.52 | 3.0 | 1 |
| A549 CHEMBL392 | IC50 | 7.96 | 7.96 | 11.0 | 1 |
| LoVo CHEMBL614721 | IC50 | 7.09 | 7.09 | 81.0 | 1 |
| NCI-H1975 CHEMBL614348 | IC50 | 7.08 | 7.08 | 84.0 | 1 |
| COLO 205 CHEMBL614561 | IC50 | 7.02 | 7.02 | 96.0 | 1 |
| HeLa CHEMBL399 | IC50 | 6.9 | 6.9 | 125.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| AUC | 748.96 | ng.hr.mL-1 | Mus musculus |
| AUC | 168.07 | ng.hr.mL-1 | Mus musculus |
| CL | 10.76 | ml/hr | Mus musculus |
| CL | 47.64 | ml/hr | Mus musculus |
| Cmax | 3157.0 | nM | Mus musculus |
| Cmax | 642.41 | nM | Mus musculus |
| F | 22.4 | % | Mus musculus |
| MRT | 0.23 | hr | Mus musculus |
| MRT | 1.15 | hr | Mus musculus |
| T1/2 | 1.03 | hr | Mus musculus |
| T1/2 | 1.46 | hr | Mus musculus |
| Tmax | 0.17 | hr | Mus musculus |
| Tmax | 0.33 | hr | Mus musculus |
Activity Data Samples
Top measurements by pChEMBL value
| Target | Type | Rel. | Value | Units | pChEMBL | Assay | PubMed |
|---|---|---|---|---|---|---|---|
| Raji | IC50 | = | 2.0 | nM | 8.7 | Cytotoxicity against human Raji assessed as reduction in cell viability measured... | 32650182 |
| HCT-116 | IC50 | = | 3.0 | nM | 8.52 | Cytotoxicity against human HCT-116 assessed as reduction in cell viability measu... | 32650182 |
| A549 | IC50 | = | 11.0 | nM | 7.96 | Cytotoxicity against human A549 assessed as reduction in cell viability measured... | 32650182 |
| LoVo | IC50 | = | 81.0 | nM | 7.09 | Cytotoxicity against human LoVo assessed as reduction in cell viability measured... | 32650182 |
| NCI-H1975 | IC50 | = | 84.0 | nM | 7.08 | Cytotoxicity against human NCI-H1975 assessed as reduction in cell viability mea... | 32650182 |
| COLO 205 | IC50 | = | 96.0 | nM | 7.02 | Cytotoxicity against human COLO 205 assessed as reduction in cell viability meas... | 32650182 |
| HeLa | IC50 | = | 125.0 | nM | 6.9 | Cytotoxicity against human Hela assessed as reduction in cell viability measured... | 32650182 |
Literature References
| PubMed | DOI | Target Context | # Activities |
|---|---|---|---|
| 32650182 | 10.1016/j.ejmech.2020.112528 | ADMET | 29 |
| 32650182 | 10.1016/j.ejmech.2020.112528 | HCT-116 | 14 |
| 32650182 | 10.1016/j.ejmech.2020.112528 | Raji | 13 |
| 32650182 | 10.1016/j.ejmech.2020.112528 | DNA topoisomerase 1 | 3 |
| 32650182 | 10.1016/j.ejmech.2020.112528 | No relevant target | 3 |
| 32650182 | 10.1016/j.ejmech.2020.112528 | A549 | 1 |
| 32650182 | 10.1016/j.ejmech.2020.112528 | LoVo | 1 |
| 32650182 | 10.1016/j.ejmech.2020.112528 | COLO 205 | 1 |
| 32650182 | 10.1016/j.ejmech.2020.112528 | HeLa | 1 |
| 32650182 | 10.1016/j.ejmech.2020.112528 | NCI-H1975 | 1 |
Data from ChEMBL 36 via Core Engine